CTSH or EPAM: Which Is the Better Value Stock Right Now?

Cognizant (CTSH) is presented as a potentially better value stock compared to EPAM Systems (EPAM) based on a recent analysis utilizing the Zacks Rank and Value Style Scores system; CTSH holds a Zacks Rank of #2 (Buy) versus EPAM's #3 (Hold), alongside a Value grade of B compared to EPAM's C. Key valuation metrics favor CTSH, including a lower forward P/E ratio (15.58 vs 16.42), PEG ratio (1.81 vs 1.84), and P/B ratio (2.62 vs 2.76), suggesting a stronger earnings outlook and potentially undervalued status relative to EPAM.

Analysis

Cognizant (CTSH) emerges as a potentially more attractive value investment compared to Epam (EPAM) within the Computers - IT Services sector, based on an analysis utilizing the Zacks Rank system and associated Value Style Scores. CTSH currently holds a Zacks Rank of #2 (Buy), signifying a stronger positive trend in earnings estimate revisions than EPAM, which has a Zacks Rank of #3 (Hold). This improved earnings outlook for CTSH, coupled with its Value grade of B, contrasts with EPAM's C grade. Key valuation metrics further support this assessment: CTSH's forward P/E ratio stands at 15.58, below EPAM's 16.42. Additionally, CTSH exhibits a slightly more favorable PEG ratio of 1.81 compared to EPAM's 1.84, and its Price-to-Book (P/B) ratio of 2.62 is also lower than EPAM's 2.76. These quantitative indicators collectively suggest that CTSH is trading at more compelling valuation multiples and may offer a superior value proposition at its current share price levels relative to EPAM.

Key Decisions for Investors

• Investors focused on value within the IT Services space should consider Cognizant (CTSH) as potentially offering a better risk-reward profile than Epam (EPAM) due to its more favorable valuation metrics and stronger earnings outlook indicated by its Zacks Rank.
• Monitor ongoing earnings estimate revisions for both CTSH and EPAM, as sustained positive revisions for CTSH would further validate its current Buy rating and value appeal, while any deterioration could alter the comparative assessment.
• Given CTSH's B Value grade and superior metrics across P/E, PEG, and P/B ratios, an overweight position in CTSH relative to EPAM might be warranted for value-oriented portfolios, contingent on individual risk tolerance and broader market analysis.